ARTICLE | Product Development
Scripps, HKU structural study keys in on COVID-19 mAb target
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
April 4, 2020 2:15 AM UTC
A team from Scripps Research Institute and the University of Hong Kong has identified a target site for neutralizing antibody therapies against COVID-19.
The site was discovered using the neutralizing mAb dubbed CR3022, which was derived from a recovered SARS patient and binds the virus’ spike, a protein trimer that mediates host cell entry. ...
BCIQ Target Profiles